Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Andrology

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 16 articles:
HTML format
Text format



Single Articles


    March 2018
  1. ALIFRANGIS C, Wilson P, Shamash J
    Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment
    Eur J Cancer. 2018 Mar 31. pii: S0959-8049(18)30226.
    PubMed     Text format    


  2. FRESNEAU B, Orbach D, Faure-Conter C, Sudour-Bonnange H, et al
    Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
    Eur J Cancer. 2018;95:11-19.
    PubMed     Text format     Abstract available


  3. SEIDEL C, Daugaard G, Tryakin A, Necchi A, et al
    Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
    Eur J Cancer. 2018;94:16-25.
    PubMed     Text format     Abstract available


    January 2018
  4. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    PubMed     Text format     Abstract available


    November 2017
  5. LORIOT Y, Pagliaro L, Flechon A, Mardiak J, et al
    Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Eur J Cancer. 2017;87:140-146.
    PubMed     Text format     Abstract available


    October 2017
  6. DE LA PENA H, Sharma A, Glicksman C, Joseph J, et al
    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
    Eur J Cancer. 2017;84:354-359.
    PubMed     Text format     Abstract available


  7. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Text format     Abstract available


    July 2017
  8. BANDAK M, Jorgensen N, Juul A, Lauritsen J, et al
    Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
    Eur J Cancer. 2017;84:9-17.
    PubMed     Text format     Abstract available


    May 2017
  9. ZSCHABITZ S, Lasitschka F, Hadaschik B, Hofheinz RD, et al
    Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Eur J Cancer. 2017;76:1-7.
    PubMed     Text format     Abstract available


    March 2017
  10. GIZZI M, Oberic L, Massard C, Poterie A, et al
    Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].
    Eur J Cancer. 2017 Mar 7. pii: S0959-8049(17)30740.
    PubMed     Text format    


    November 2016
  11. GIZZI M, Oberic L, Massard C, Poterie A, et al
    Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
    Eur J Cancer. 2016;69:151-157.
    PubMed     Text format     Abstract available


    June 2016
  12. LUBBERTS S, Boer H, Altena R, Meijer C, et al
    Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy.
    Eur J Cancer. 2016;63:180-188.
    PubMed     Text format     Abstract available


    March 2016
  13. VAN DER SCHOOT GG, Westerink NL, Lubberts S, Nuver J, et al
    Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.
    Eur J Cancer. 2016;59:134-141.
    PubMed     Text format     Abstract available


    January 2016
  14. BOER H, Westerink NL, Altena R, Nuver J, et al
    Single-nucleotide polymorphism in the 5-alpha-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
    Eur J Cancer. 2016;54:104-111.
    PubMed     Text format     Abstract available


    September 2015
  15. TRAMA A, Foschi R, Larranaga N, Sant M, et al
    Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study.
    Eur J Cancer. 2015 Sep 6. pii: S0959-8049(15)00707.
    PubMed     Text format     Abstract available


    December 2014
  16. SCHNEIDER DT, Orbach D, Cecchetto G, Stachowicz-Stencel T, et al
    Ovarian Sertoli Leydig cell tumours in children and adolescents: An analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT).
    Eur J Cancer. 2014 Dec 13. pii: S0959-8049(14)01137.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Andrology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: